Role of P-glycoprotein in drug disposition

Therapeutic Drug Monitoring

Volumn 22, Issue 1, 2000, Pages 137-140

  Tanigawara, Yusuke ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

ABC transporter; Blood brain barrier; Digoxin; Multidrug resistance; Renal excretion

Indexed keywords

ABC TRANSPORTER; CYCLOSPORIN A; DIGOXIN; GLYCOPROTEIN P; QUINIDINE; VERAPAMIL; XENOBIOTIC AGENT;

ANIMAL CELL; ARTICLE; BILIARY EXCRETION; BLOOD BRAIN BARRIER; CANCER; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG MECHANISM; HUMAN; HUMAN CELL; KIDNEY TUBULE EXCRETION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; URINARY EXCRETION;

ANIMALS; BRAIN CHEMISTRY; HUMANS; KIDNEY; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 0033975157     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200002000-00029     Document Type: Article

References (24)

1. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug resistance (MDR1) gene. J Biol Chem 1987;262:505-8.
2. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug resistance gene product in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-8.
3. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8.
4. Ueda K, Okamura N, Hirai M, et al. Human p-glycoprotein transports Cortisol, aldosterone, and dexamethasone but not progesterone. J Biol Chem 1992;267(34):24248-52.
5. Tanigawara Y, Okamura N, Hirai M, et al. Transport of digoxin by human p-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992;263(2):840-5.
6. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human p-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993;268(9):6077-80.
7. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEES Lett 1993;324(1):99-102.
8. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998;251:252-61.
9. Hori R, Okamura N, Aiba T, Tanigawara Y. Role of p-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993;266(3):1620-5.
10. Okamura N, Hirai M, Tanigawara Y, et al. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter p-glycoprotein in the kidney. J Pharmacol Exp Ther 1993;266(3):1614-9.
11. Hori R, Tanigawara Y, Hirai M, Yasuhara M, Ueda K, Komano T. Substrates for P-glycoprotein in Kidney. In: Keppler D and Jungermann K, eds. Transport in the Liver. Dordrecht: Kluwer Academic Publishers; 1994:223-32.
12. Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
13. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997;94: 4028-33.
14. Schinkel AH. Pharmacologic insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther 1998;36:9-13.
15. Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Advanced Drug Delivery Reviews 1999;36:179-94.
16. Smitt JJM, Schinkel AH, Oude Elferink RPJ, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451-62.
17. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24.
18. Ueda K, Saeki T, Hirai M, et al. Human P-glycoprotein as a multidrug transporter analyzed by using transepithelial transport system. Jap J Physiol 1994;44(Suppl2):S67-71.
19. Ueda K, Kino K, Taguchi Y, et al. Role of P-glycoprotein in the transport of hormones and peptides. In: Gupta S and Tsuruo T, eds. Multidrug Resistance in Cancer Cells. Sussex, England: John Wiley & Sons;1996:303-19.
20. Tanaka K, Hirai M, Tanigawara Y, et al. Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via p-glycoprotein. Pharm Res 1996;13:1073-7.
21. Tanaka K, Hirai M, Tanigawara Y, et al. Relationship between expression level of p-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene. Biochem Pharmacol 1997;53(5):741-6.
22. Kusunoki N, Takara K, Tanigawara Y, et al. Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human p-glycoprotein. Jpn J Cancer Res 1998;89(11):1220-8.
23. Ohtsu T, Tanigawara Y, Fujii H, et al. The effect of intravenous SDZ PSC833 on the pharmacokinetics and pharmacodynamics of doxorubicin in a phase I trial. Ann Oncol 1998;9(Suppl2):552.
24. Advani R, Saba HI, Tallman MS, et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999;93:787-95.